1. Shaaban AM, Rezvani M, Haroun RR, et al. Gestational trophoblastic disease: clinical and imaging features. Radiographics. 2017;37(2):681-700. [
DOI:10.1148/rg.2017160140]
2. Ngan HY, Seckl MJ, Berkowitz RS, et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynecol Obstet. 2015;131:S123-S6. [
DOI:10.1016/j.ijgo.2015.06.008]
3. Usui H, Qu J, Sato A, et al. Gestational trophoblastic neoplasia from genetically confirmed hydatidiform moles: prospective observational cohort study. Int J Gynecol Cancer. 2018;28(9):1772-80. [
DOI:10.1097/IGC.0000000000001374]
4. Niemann I, Vejerslev LO, Frøding L , et al. Gestational trophoblastic diseases-clinical guidelines for diagnosis, treatment, follow-up, and counselling. Dan Med J. 2015;62(11):A5082.
5. Lertkhachonsuk A, Hanvoravongchai P. Comparison of cost-effectiveness between actinomycin D versus methotrexate-folinic acid in the treatment of low-risk gestational trophoblastic neoplasia. J Rep Med. 2016;61(5-6):230-4.
6. Braga A, Maestá I, Matos M, Elias KM, Rizzo J, Viggiano MGC. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation. Gynecol Oncol. 2015;139(2):283-7. [
DOI:10.1016/j.ygyno.2015.09.012]
7. Verit FF. May platelet count be a predictor of low-risk persistent gestational trophoblastic disease? Arch Gynecol Obstet. 2011;283(4):695-9. [
DOI:10.1007/s00404-010-1408-2]
8. Whitworth JM, Straughn JM, Atigadda VR, Muccio DD, Buchsbaum DJ. The use of retinoids in ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2012;22(2):191-8. [
DOI:10.1097/IGC.0b013e318236a2ec]
9. Sun P, Wu Q, Ruan G, et al. Expression patterns of maspin and mutant p53 are associated with the development of gestational trophoblastic neoplasia. Oncol Lett. 2016;12(5):3135-42. [
DOI:10.3892/ol.2016.5074]
10. Zadeh FJ, Janatmakan F, Soltanzadeh M, Zamankhani M. Investigating the effect of fibrinogen injection on bleeding in coronary artery bypass surgery: A clinical trial. Anesthesiol Pain Med. 2019;9(4): e92165 [
DOI:10.5812/aapm.92165]
11. Wu M, Zhang H, Hu J, et al. Isoalantolactone inhibits UM-SCC-10A cell growth via cell cycle arrest and apoptosis induction. PloS one. 2013;8(9). [
DOI:10.1371/journal.pone.0076000]
12. Kolusari A, Kurdoglu M, Yildizhan R, et al. Catalase activity, serum trace element and heavy metal concentrations, and vitamin A, D and E levels in pre-eclampsia. J Int Med Res. 2008;36(6):1335-41. [
DOI:10.1177/147323000803600622]
13. Al Riyami N, Al Riyami M, Al Thuriya Al Hajri SA, Saidi BS, Al Kalbani M. Gestational trophoblastic disease at Sultan Qaboos University Hospital: Prevalence, risk factors, histological features, sonographic findings, and outcomes. Oman Med J. 2019;34(3):200. [
DOI:10.5001/omj.2019.39]
14. Andrijono A, Muhilal M. Prevention of post-mole malignant trophoblastic disease with vitamin A. Asian Pac J Cancer Prev. 2010;11(2):567-70.
15. Zadeh FJ, Moadeli M, Soltanzadeh M, Janatmakan F. Effect of remote ischemic preconditioning on troponin I in CABG. Anesthesiol Pain Med. 2017;7(4). [
DOI:10.5812/aapm.12549]
16. Cunningham FG, Leveno K, Bloom S, Hauth J, Gilstrap L, Wenstrom K. Gestational trophoblastic disease. Williams Obstetrics 22nd ed New York: McGraw Hill. 2005.
17. Stevens F, Katzorke N, Tempfer C, et al. Gestational trophoblastic disorders: an update in 2015. Geburtshilfe Frauenheilkunde. 2015;75(10):1043-50. [
DOI:10.1055/s-0035-1558054]
18. Feizollahi N, Zayeri ZD, Moradi N, Zargar M, Rezaeeyan H. The effect of coagulation factors polymorphisms on abortion. Front Biol. 2018;13(3):190-6. [
DOI:10.1007/s11515-018-1500-8]
19. Mazul AL, Weinberg CR, Engel SM, et al. Neuroblastoma in relation to joint effects of vitamin A and maternal and offspring variants in vitamin A-related genes: A report of the Children's Oncology Group. Cancer Epidemiol. 2019;61:165-71. [
DOI:10.1016/j.canep.2019.06.009]
20. Berkowitz RS, Cramer DW, Bernstein MR, Cassells S, Driscoll SG, Goldstein DP. Risk factors for complete molar pregnancy from a case-control study. AmJ Obstet Gynecol. 1985;152(8):1016-20. [
DOI:10.1016/0002-9378(85)90550-2]
21. Lawler S, Pickthall V, Fisher R, Povey S, Evans MW, Szulman A. Genetic studies of complete and partial hydatidiform moles. The Lancet. 1979;314(8142):580. [
DOI:10.1016/S0140-6736(79)91632-5]
22. Kolusari A, Adali E, Kurdoglu M, Yildizhan R, Cebi A, Edirne T, et al. Catalase activity, serum trace element and heavy metal concentrations, vitamin A, vitamin D and vitamin E levels in hydatidiform mole-Serum levels of catalase, Zn, Co, and vitamin A, D, and E were significantly lower in patients with hydatiform mole compared with healthy pregnant women and non pregnant controls. Clin Experiment Obstet Gynecol. 2009;36(2):102. [
DOI:10.1177/147323000803600622]
23. Bakhtiyari M, Mirzamoradi M, Kimyaiee P, Aghaie A, Mansournia MA, Ashrafi-vand S, et al. Postmolar gestational trophoblastic neoplasia: beyond the traditional risk factors. Fertil Steril. 2015;104(3):649-54. [
DOI:10.1016/j.fertnstert.2015.06.001]
24. Ghasemian S, Yousefi Z, Farazestanian M, Seresht LM, Foroughipour M, Akhlaghi S. Effect of combination therapy of methotrexate with vitamin A in patients with low risk GTN (Gestational Trophoblastic Neoplasia). IranJ Pharmaceut Res. 2018;17(Suppl):38.
